Company Filing History:
Years Active: 2021-2025
Title: Velupillai Puvanesarajah: Innovator in Pneumococcal Vaccine Technology
Introduction
Velupillai Puvanesarajah is a prominent inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of vaccine technology, particularly in the development of multivalent pneumococcal vaccines. With a total of five patents to his name, Puvanesarajah is recognized for his innovative approaches to preventing and treating pneumococcal infections.
Latest Patents
Among his latest patents are technologies focused on multivalent pneumococcal vaccines. These patents aim to enhance the prevention and treatment of pneumococcal infections, showcasing his commitment to advancing public health through innovative solutions.
Career Highlights
Puvanesarajah currently works at Affinivax, Inc., where he continues to develop groundbreaking vaccine technologies. His work has positioned him as a key figure in the fight against pneumococcal diseases, contributing to the overall improvement of healthcare outcomes.
Collaborations
Throughout his career, Puvanesarajah has collaborated with notable professionals in the field, including Richard Malley and Yingjie Lu. These partnerships have further enriched his research and development efforts, leading to impactful advancements in vaccine technology.
Conclusion
Velupillai Puvanesarajah's work in pneumococcal vaccine technology exemplifies the vital role of inventors in addressing global health challenges. His innovative contributions continue to pave the way for advancements in medical science and public health.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.